Arlington Financial Advisors LLC Sells 1,363 Shares of Amgen Inc. $AMGN

Arlington Financial Advisors LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 5.2% in the second quarter, Holdings Channel reports. The institutional investor owned 24,884 shares of the medical research company’s stock after selling 1,363 shares during the period. Amgen accounts for approximately 1.1% of Arlington Financial Advisors LLC’s portfolio, making the stock its 24th biggest position. Arlington Financial Advisors LLC’s holdings in Amgen were worth $6,948,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Brighton Jones LLC increased its position in Amgen by 23.5% during the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. GAMMA Investing LLC increased its position in Amgen by 40.2% during the 1st quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock valued at $3,662,000 after buying an additional 3,369 shares in the last quarter. Acropolis Investment Management LLC increased its position in Amgen by 7.8% during the 1st quarter. Acropolis Investment Management LLC now owns 1,097 shares of the medical research company’s stock valued at $342,000 after buying an additional 79 shares in the last quarter. Mission Wealth Management LP increased its position in Amgen by 5.0% during the 1st quarter. Mission Wealth Management LP now owns 10,991 shares of the medical research company’s stock valued at $3,424,000 after buying an additional 528 shares in the last quarter. Finally, Blackston Financial Advisory Group LLC increased its position in Amgen by 8.5% during the 1st quarter. Blackston Financial Advisory Group LLC now owns 1,148 shares of the medical research company’s stock valued at $358,000 after buying an additional 90 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on AMGN. Cantor Fitzgerald reissued a “neutral” rating and issued a $305.00 target price on shares of Amgen in a report on Tuesday, June 24th. Piper Sandler lifted their target price on Amgen from $328.00 to $342.00 and gave the stock an “overweight” rating in a report on Monday, August 25th. William Blair reissued an “outperform” rating on shares of Amgen in a report on Tuesday, June 24th. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a report on Saturday. Finally, Raymond James Financial began coverage on Amgen in a report on Wednesday, September 3rd. They issued a “market perform” rating for the company. Eight research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $309.42.

Amgen Stock Performance

AMGN stock opened at $293.85 on Wednesday. The company has a market cap of $158.20 billion, a P/E ratio of 24.03, a price-to-earnings-growth ratio of 2.54 and a beta of 0.49. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $335.88. The company has a debt-to-equity ratio of 7.24, a current ratio of 1.31 and a quick ratio of 0.98. The stock’s fifty day moving average price is $286.46 and its 200-day moving average price is $287.37.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same period last year, the business posted $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.2%. Amgen’s payout ratio is 77.84%.

Insiders Place Their Bets

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the transaction, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.69% of the company’s stock.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.